Sign in Create account

Kabra Drugs Ltd

Healthcare · Pharmaceuticals & Biotechnology

BSE: 524322
₹19.49
▼ -1.19 (-5.75%)
Sept. 30, 2026 · BSE · bse_bhavcopy
Quality
61/100
Moderate
Valuation
96/100
Undervalued
Momentum
50/100
Neutral

QVM read Cheap on its own multiples Quality Moderate, Valuation Undervalued, Momentum Neutral

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹46 Cr
PE (TTM)
6.1
Industry median 36.1 (152 companies)
Price to Book
1.6
PEG (TTM)
0.0
Institutions holding %
Data unavailable.
Piotroski Score
Data unavailable.
Relative return vs Nifty50, qtr %
Data unavailable.
Relative return vs Sector, qtr %
146.4
Free Cash Flow
₹-10 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
528.57%
as of June 30, 2026
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
247.63%
as of June 30, 2026
Industry median 6.21% (175 companies)
Operating Revenue Growth (TTM)
1086.60%
as of June 30, 2026
Industry median 9.08% (175 companies)
Profit Growth (YoY)
524.60%
as of June 30, 2026
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
546.39%
as of June 30, 2026
Industry median 14.05% (173 companies)
Current Ratio
1.49
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
0.01
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
403.93
as of June 30, 2026
Industry median 10.58 (182 companies)
Net Margin
4.59%
as of June 30, 2026
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
6.16%
as of June 30, 2026
Industry median 14.22% (181 companies)
Operating Margin (TTM)
6.90%
as of June 30, 2026
Industry median 12.41% (182 companies)
Return on Assets
0.47%
as of March 31, 2026
Industry median 5.54% (180 companies)
Return on Capital Employed
19.32%
as of March 31, 2026
Industry median 12.43% (181 companies)
Return on Equity
1.36%
as of March 31, 2026
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

1 of 5 met
  • No Quality score is Strong (70 or more)
  • Yes Debt to equity is below 0.5 (0.01)
  • No Return on equity is 15% or more (1.4%)
  • No Net cash flow for the latest year is positive
  • No Cash from operations is higher than the year before

Ownership

2 of 2 met
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.0% pledged)

Peer comparison

3 of 3 met
  • Yes 1-year return beats the industry median
  • Yes Revenue growth beats the industry median
  • Yes Profit growth beats the industry median

Value and momentum

3 of 6 met
  • Yes Price sits in the Buy zone of its own historical PE range (Buy Zone)
  • Yes Valuation score is Undervalued (70 or more)
  • No Momentum score is Bullish (70 or more)
  • No Price is above the 5, 10 and 20 day averages
  • Yes Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs SENSEX)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
-5.8%
Low 19.1000 · High 21.9000
1W return
1.9%
Low 18.0000 · High 22.4000
1M return
-1.7%
Low 18.0000 · High 22.4000
52W return
146.4%
Low 18.0000 · High 26.2000
Lifetime High ₹158.2000 (Feb. 5, 2015)
Lifetime Low ₹0.5200 (March 27, 2019)

Full price history and technicals →

Technicals

Full technicals, indicators & Volume/Delivery →

EMA & SMA

Bullish3
Bearish3
5D
19.8
10D
19.7
20D
19.6
50D
17.4
100D
13.7
200D
8.0

Delivery and volume

Day avg. delivery
71.6%
Week avg. delivery
69.0%
Month avg. delivery
69.2%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

20.16
Pivot
First resistance21.23
Second resistance22.96
Third resistance24.03
First support18.43
Second support17.36
Third support15.63
Day RSI51.2
Day MFI52.0
Day MACD0.32
Day MACD signal0.44

Beta

1M-1.89
3M-1.62
1Y-1.62
3Y-0.35

Price change analysis

↓ -1.7%
Over 1 Month
LowHigh
18.0022.40
↑ 146.4%
Over 3 Months
LowHigh
18.0026.20
↑ 146.4%
Over 6 Months
LowHigh
18.0026.20
↑ 146.4%
Over 1 Year
LowHigh
18.0026.20
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →
Current PE 6.1 (own history: 2.5–33.0)
Buy Zone

Financials

View full financials, peers & valuation multiples →
Revenue (June 30, 2026)
₹46 Cr
Net profit (June 30, 2026)
₹2 Cr
Basic EPS (June 30, 2026)
₹0.9000

Ranks #154 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Sep 2019
  • Promoter23.88%

Largest holders

Data unavailable.

Historical promoter holding

Promoters holdings were unchanged at 23.88% in Sep 2019 qtr

All shareholding details →

Deals (Bulk & Block)

All 98 deals, with filters and CSV →
DateClientDealActionQuantityPriceExchange
2 Jan 2026 KRUTI SEVANTI DOSHI Bulk Sell 130,810 31.8200 BSE
1 Jan 2026 KRUTI SEVANTI DOSHI Bulk Sell 143,190 31.2000 BSE
24 Dec 2025 KRUTI SEVANTI DOSHI Bulk Sell 126,000 30.1900 BSE
22 Dec 2025 MIRAL HEMANTBHAI BHOOT Bulk Sell 119,000 27.5500 BSE
20 Nov 2025 SOUMYA MALANI . Bulk Buy 150,000 27.6500 BSE
20 Nov 2025 VIJAY KUMAR REDDY VEERAMREDDY Bulk Sell 150,519 27.6300 BSE
20 Nov 2025 SELVAMURTHY AKILANDESWARI Bulk Buy 191,422 26.8900 BSE
18 Jul 2025 ISHAAN TRADEFIN LLP Bulk Buy 7,717 21.8700 BSE
18 Jul 2025 ISHAAN TRADEFIN LLP Bulk Sell 136,442 22.2600 BSE
16 Jul 2025 ISHAAN TRADEFIN LLP Bulk Buy 137,393 20.2500 BSE

All bulk and block deals →

Corporate Announcements

All 6 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
1 Oct 2026 AGM/EGM Kabra Drugs Ltd - 524322 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
30 Sep 2026 AGM/EGM Kabra Drugs Ltd - 524322 - Shareholder Meeting / Postal Ballot-Outcome of AGM
28 Sep 2026 Insider Trading / SAST Kabra Drugs Ltd - 524322 - Closure of Trading Window
9 Sep 2026 Company Update Kabra Drugs Ltd - 524322 - Announcement under Regulation 30 (LODR)-Newspaper Publication
3 Sep 2026 Corp. Action Kabra Drugs Ltd - 524322 - Book Closure And Schedule Of Events For E-Voting.
2 Sep 2026 Board Meeting Kabra Drugs Ltd - 524322 - Board Meeting Outcome for Outcome Of Board Meeting Held On 02Nd September 2026

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Low financial leverage (Debt/Equity 0.01)
  • Comfortable interest coverage (403.9x)
  • Strong revenue growth YoY (546.4%)

Weaknesses

  • Low Return on Equity (1.4%)
  • Thin net profit margin (4.6%)

Opportunities

  • PEG below 1 (0.04) -- earnings growth outpacing its own valuation
  • PE below 15 (6.1) relative to a typical growth business

Threats

Data unavailable.

Board of directors and corporate information →

F&O

View F&O, Options & Backtest →

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about Kabra Drugs Ltd

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.